The final OS data remain encouraging across all cohorts, which suggests that durvalumab monotherapy has clinical antitumor activity in patients with advanced NSCLC who have undergone multiple lines of therapy, including EGFR+/ALK+ patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.